A detailed history of Pegasus Partners Ltd. transactions in Abb Vie Inc. stock. As of the latest transaction made, Pegasus Partners Ltd. holds 4,999 shares of ABBV stock, worth $878,174. This represents 0.09% of its overall portfolio holdings.

Number of Shares
4,999
Previous 4,999 -0.0%
Holding current value
$878,174
Previous $857,000 15.17%
% of portfolio
0.09%
Previous 0.09%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

SELL
$154.79 - $180.76 $15,479 - $18,076
-100 Reduced 1.96%
4,999 $857,000
Q1 2024

Apr 24, 2024

BUY
$159.82 - $182.1 $14,223 - $16,206
89 Added 1.78%
5,099 $928,000
Q4 2023

Feb 12, 2024

SELL
$137.6 - $154.97 $18,851 - $21,230
-137 Reduced 2.66%
5,010 $776,000
Q3 2023

Nov 13, 2023

BUY
$133.59 - $154.65 $87,635 - $101,450
656 Added 14.61%
5,147 $767,000
Q2 2023

Aug 04, 2023

SELL
$132.51 - $164.9 $795 - $989
-6 Reduced 0.13%
4,491 $605,000
Q3 2022

Nov 10, 2022

SELL
$134.21 - $153.93 $92,873 - $106,519
-692 Reduced 13.34%
4,497 $604,000
Q2 2022

Aug 12, 2022

BUY
$137.62 - $174.96 $9,633 - $12,247
70 Added 1.37%
5,189 $795,000
Q1 2022

May 13, 2022

BUY
$131.98 - $163.75 $277,949 - $344,857
2,106 Added 69.9%
5,119 $830,000
Q4 2021

Feb 09, 2022

SELL
$107.43 - $135.93 $600,211 - $759,440
-5,587 Reduced 64.97%
3,013 $408,000
Q3 2021

Nov 12, 2021

BUY
$106.4 - $120.78 $212 - $241
2 Added 0.02%
8,600 $928,000
Q2 2021

Aug 13, 2021

BUY
$105.21 - $117.21 $315 - $351
3 Added 0.03%
8,598 $968,000
Q1 2021

May 14, 2021

BUY
$102.3 - $112.62 $306 - $337
3 Added 0.03%
8,595 $930,000
Q4 2020

Feb 12, 2021

BUY
$80.49 - $108.67 $241 - $326
3 Added 0.03%
8,592 $921,000
Q3 2020

Nov 13, 2020

BUY
$85.91 - $100.83 $257 - $302
3 Added 0.03%
8,589 $752,000
Q2 2020

Aug 12, 2020

BUY
$73.37 - $98.18 $17,315 - $23,170
236 Added 2.83%
8,586 $843,000
Q1 2020

May 11, 2020

SELL
$64.5 - $97.79 $184,083 - $279,092
-2,854 Reduced 25.47%
8,350 $636,000
Q4 2019

Feb 12, 2020

SELL
$72.13 - $90.25 $111,729 - $139,797
-1,549 Reduced 12.15%
11,204 $992,000
Q3 2019

Oct 24, 2019

SELL
$62.98 - $75.72 $493,637 - $593,493
-7,838 Reduced 38.07%
12,753 $966,000
Q2 2019

Jul 30, 2019

SELL
$65.7 - $83.98 $170,031 - $217,340
-2,588 Reduced 11.17%
20,591 $1.5 Million
Q1 2019

May 13, 2019

BUY
$77.14 - $90.79 $439,003 - $516,685
5,691 Added 32.54%
23,179 $1.87 Million
Q4 2018

Feb 01, 2019

SELL
$77.85 - $96.01 $736,383 - $908,158
-9,459 Reduced 35.1%
17,488 $1.61 Million
Q3 2018

Nov 07, 2018

BUY
$88.91 - $98.84 $24,094 - $26,785
271 Added 1.02%
26,947 $2.55 Million
Q2 2018

Jul 27, 2018

BUY
$89.78 - $106.23 $173,814 - $205,661
1,936 Added 7.83%
26,676 $2.47 Million
Q1 2018

May 09, 2018

BUY
$92.01 - $123.21 $1.35 Million - $1.81 Million
14,690 Added 146.17%
24,740 $2.34 Million
Q4 2017

Feb 08, 2018

BUY
$89.56 - $98.21 $27,494 - $30,150
307 Added 3.15%
10,050 $972,000
Q3 2017

Nov 09, 2017

BUY
$69.85 - $89.22 $680,548 - $869,270
9,743
9,743 $866,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $311B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Pegasus Partners Ltd. Portfolio

Follow Pegasus Partners Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pegasus Partners Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Pegasus Partners Ltd. with notifications on news.